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Abstract
The birth of a baby with atypical external and/or internal genitalia is a family 
crisis that requires the interaction between multidisciplinary group physicians 
including pediatric urologists, pediatric endocrinologists, medical geneticists, 
genetic counsellors, gynecologists, psychologists/psychiatrists and social workers 
with expertise in this field. Following each of the specialists’ assessment the find-
ings, plan for investigations, the psychosocial situation and gender assignment 
and treatment should be reviewed among the group members prior to meeting 
the family. Following the group discussion the information should be presented to 
the parents using easy to understand language with visual aids and their questions 
should be answered so that they can make an informed decision regarding gender 
assignment, surgical options, where medically indicated, and hormone treatment. 
Potential for sexual relationships and fertility preservation should be discussed. The 
birth of a baby with abnormalities may be associated with mother/parental guilt 
feeling and the point that there is nothing that they did or did not do that caused 
the newborn’s condition. Disorder of sex development (DSD) can be divided into 
isolated and non-isolated according to the finding on physical examination and 
should be further classified into abnormalities of chromosomal abnormalities, 
gonadal defect, internal and external genital abnormalities. Investigations should 
be directed by the physical examination findings and the results of the radiological, 
endocrine and genetic investigation including FISH analysis, microarray analysis, 
DNA analysis using a variety of DSD panels and, when required, whole exome/
genome sequencing.
Keywords: sex development, sex differentiation, gonadal differentiation,  
genital abnormalities, congenital adrenal hyperplasia, androgen secretion,  
androgen action, androgen insensitivity, gender assignment, psychosocial status
1. Introduction
Sex development involves many autosomal and X-linked genes acting and inter-
acting along a short duration in a precise synergy. The process of sex determination 
includes 4 layers:
1. Determination of the chromosome sex
2. Determination of the gonadal sex
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3. Development of the internal genitalia
4. Determination of the external genitalia
DSD is a heterogeneous group of congenital abnormalities associated with 
 atypical development of the external and internal genitalia with an estimated 
incidence of 1:200–1:4500 [1]. Some of the abnormalities seem to have increased in 
incidence along the years with hypospadias reported to reach an incidence of 1:125 
newborn males and cryptorchidism reaching an incidence as high as 3% of full-
term male newborns.
The nomenclature used to describe the genital abnormalities was initially 
descriptive, and on many occasions offensive. The advances in genetics and genom-
ics knowledge substantially improved our understanding of the etiology of these 
conditions and resulted in a need to change the nomenclature. Thus, a new concept 
was introduced at the Chicago Consensus Conference 2005 [2] which defined the 
DSD as a congenital condition in which the development of chromosomal, gonadal 
or anatomical sex is atypical (instead of abnormal or ambiguous).
DSD can be divided into isolated or non-isolated/associated with other major 
abnormalities (Figure 1). When non-isolated they are usually associated with a 
variety of chromosome abnormalities, single gene or developmental field disorders 
which involve different body organ and systems (Figure 2). This review will mainly 
highlight the isolated/non-syndromic group of disorders of sex development.
In humans, the gonads are populated by primordial germ cells, deriving from 
the yolk sac wall early in week five post conception. Normally, it is the presence or 
absence of the of the SRY gene in the Y chromosome in the germ cells that starts the 
chain of events which cause the gonadal determination as testis in males. The secre-
tion of testicular hormones in males and their attachment to their action through 
receptors results in normal development of the male internal and external genitalia 
(Figures 3 and 4). The absence of the SRY gene or function and the expression 
of genes induced by them will result in the development of ovaries. The lack of 
hormones produced by the testis will determine the normal formation of female 
internal and external genitalia (Figures 3 and 4).
It was previously thought that the absence of SRY gene in the gonadal ridge will 
result in ovarian differentiation while the existence of the SRY gene will result in 
Figure 1. 
Disorders of sex development—initial assessment.
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testicular development. However it is currently clear that gonadal sex is determined 
by antagonistic actions of ovarian and testicular cascades [5, 6] around week six 
post conception. In the female embryo, high levels of retinoic acid around the 
germ cells induces the STRA8 gene expression, resulting in germ cell meiosis and 
formation of oocytes. The absence of retinoic acid in the developing testis, results 
in formation of gonocytes which differentiate into spermatogonia and proliferate 
through mitosis with the meiosis happening after puberty [7].
There are three main differences between ovarian and testicular activities 
(Figure 3):
1. The testes produce testosterone early in embryogenesis which induce the 
 formation of the male external genital while the ovaries produce hormones 
only from puberty
Figure 2. 
Differential diagnosis in isolated disorders of sex development.
Figure 3. 
Gonadal differentiation and function.
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2. Oogenesis starts and ends prior to 20 weeks gestation while spermatogenesis 
starts only at puberty
3. The ovarian hormonal production/function is linked to the process of follicle 
development and/or maintenance. The testes on the other hand can continue 
producing testosterone even in the lack of spermatogenesis.
The management of a newborn with abnormal genitalia has to be  individualized 
taking into account the specific genital abnormalities as well as the parental and 
family as a whole. The decision regarding the sex of rearing should take into 
account the, surgical and non-surgical treatment, future pubertal development 
and fertility. This should be considered an urgent clinical situation and requires 
immediate assessment and counselling, and if possible, involvement of the DSD 
multidisciplinary core team including endocrinology, clinical genetics, genetic 
counselling, urology, obstetrics and gynecology, social work and psychology/ 
psychiatry among others.
2. Sex chromosome disorders of sex development
Although the majority of sex chromosome abnormalities do not have genital 
differences as a clinical finding, some do. At conception 2% of all pregnancies 
are Turner syndrome and is one of the most common chromosome abnormality 
associated with first trimester miscarriages. The condition is highly lethal in-utero 
and thus the incidence at birth is 1:2500 female newborn. In almost 2/3 of cases, 
i.e. 60%, the karyotype is 45,X while in 15%, the condition is associated with 
mosaicism, i.e. 45, X/47,XXX, 45,X/46, XX/47,XXX, 45,X/46, XY, and 45,X/46, XX. 
Other chromosome abnormalities associated with Turner syndrome include struc-
tural abnormalities involving the X chromosome, e.g., 46,X,r(X), 46,X,Xp-, and 
Figure 4. 
Diagram of the known major genes involved in testicular and ovarian differentiation and function 
(adapted from [3, 4]).
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46,X,i(Xq) in 10% of cases, structural abnormality of the X chromosome in mosaic 
state in 10% of cases, with 5% in the other [8]. The condition can be detected 
prenatally, due to abnormalities in the lymphatic system, with the fetus present-
ing with heart lesions, specifically left-sided, hydrops fetalis, increased nuchal 
translucency or cystic hygroma. Postnatally, female babies can present with typical 
facial features, including epicanthic folds, droopy eyelids, down slanting palpebral 
fissures, micrognathia, and low set and prominent ears. The neck is often webbed 
and short with a nuchal hairline that is low, as well as swelling (lymphedema) of the 
feet and hands, and deep set nails. Left-sided cardiac anomalies are seen in 50% of 
the cases (hypoplastic left heart, coarctation of the aorta, bicuspid aortic valve, and 
aortic stenosis) with an increased risk for aortic dissection during pregnancy and 
the puerperal period if they decide to conceive using a donor egg. It is also associ-
ated with horseshoe kidneys as well as short stature, streak gonads and thus lack of 
spontaneous puberty. However, they can conceive using a donor egg.
Genetic analysis for Y chromosome material, including in a mosaic state can be 
picked up by chromosome microarray analysis and is important since girls with 
mosaicism for 46, XY [45,X/46,XY] have an increased risk for gonadoblastoma and 
dysgerminoma and may have absent uterus. A large British series in the literature, 
looking at women with Turner syndrome, showed an increased incidence not only 
of gonadoblastoma, but also uterine cancer, as well as possibly pediatric brain 
cancers. This study also demonstrated a lower incidence of breast cancer [9–11].
The incidence of Klinefelter syndrome, i.e. 47, XXY is approximately 1 in 500 
males. Clinically, they can present with testes on the smaller end of the spectrum, 
which can impact production of testosterone and normal sperm. Otherwise, they 
do not have genital differences. They have normal appearing facies but can be 
taller in height than average and about 50% develop gynecomastia at puberty. Boys 
with Klinefelter syndrome can present with neurodevelopmental/neurobehavioral 
issues; however encouraging results, for behavioral as well as for the physical 
features described above, have been seen with early administration of testosterone. 
The optimal timing and dosage of hormonal therapy has not been established and 
further studies and long term follow-up are needed prior to this becoming standard 
treatment [12].
Mosaicism for 45,X/46, XY, also previously called mixed gonadal dysgenesis, is 
a rare condition with an approximate incidence reported in Denmark of less than 
1/15,000 live births [8]. It has been suggested that transformation of the indiffer-
ent gonad to testes [13–15] is due to the existence of Y chromosome in the gonadal 
ridge. The spectrum of genital differences with this karyotype is varied, ranging 
from females presenting with Turner syndrome, to males with ambiguous genitalia, 
to phenotypically normal males. Gonadal function in most 45,X/46, XY males, even 
those with genital ambiguity, seems sufficient for spontaneous puberty and patients 
appear to benefit from GH treatment when needed [16].
3. 46, XY disorders of sex development
46, XY DSD can be divided into categories;
1. Disorders of testicular (gonadal) development
2. Disorders of androgen synthesis
Both categories lead to feminization or abnormal genitalia.
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3.1 Disorders of testicular (gonadal) development
Disorders of testicular (gonadal) development are characterized by absent 
or small testes on palpation and/or ultrasound. Müllerian structures (uterus and 
fallopian tubes) can be present with the external genitalia feminized to varying 
degrees along with decreased levels of testosterone, dehydroepiandrosterone and 
androstenedione [17].
At approximately 6 weeks, the gonads can form ovaries or testis [3]. The process 
of testicular differentiation involves multiple genes (Figure 4). Mutations causing 
haploinsufficiency with a loss of function and duplication with gain of function are 
known to be associated with 46, XY gonadal DSD. The SRY gene encodes a tran-
scription factor that causes a cascade effect allowing the bipotential gonad to form 
testis [18]. Pathogenic variants and deletions involving the SRY gene lead to com-
plete gonadal dysgenesis or 46, XY pure gonadal dysgenesis. Approximately 15% of 
individuals with Swyer syndrome have this finding. Swyer Syndrome is also known 
as 46, XY complete gonadal dysgenesis or 46, XY pure gonadal dysgenesis. Patients 
with Swyer Syndrome present with female internal and external genitalia.
The SRY and NR5A1 genes activate SOX9 and the anti-Müllerian hormone 
(AMH) formation and lead to secretion by the Sertoli cells [19]. Mutations in the 
SOX9 gene [OMIM # 608160] presents with campomelic dysplasia and sex rever-
sal in 50% of the cases with 46, XY. A heterozygous deletion of approximately 
240 kb (between 405 kb – 645 kb upstream of the SOX9 transcription start site) 
was reported with 46,XY with a normal external female phenotype and severe 
ambiguous and asymmetric external genitalia [20]. Another case presenting as 46, 
XX male resulted from a heterozygous duplication upstream of the SOX9 gene on 
 chromosome 17 [21].
The ligand FGF9 and the signaling molecule WNT4 are expressed in the 
undifferentiated gonad. Further in development they continue to be expressed in 
the ovary and the testis providing opposing signals that determine gonadal dif-
ferentiation. FGF9 promotes testicular differentiation and the Wnt family member 
(WNT)/R-spondin 1 signaling and forkhead box L2 (FOXL2) drive female sex 
determination in XX gonads and promotes ovarian differentiation. Testicular for-
mation is established when the SRY gene initiates a feed-forward loop. SRY interacts 
with SOX9 and FGF9 leading to upregulation of FGF9 and repression of WNT4. 
The receptor for the FGF9 in the developing testis is FGFR2 [22]. NR5A1 gene 
(also known as SF-1) (OMIM 184757) is another important gene for the bipotential 
gonad. This orphan nuclear receptor is expressed in multiple locations including 
hypothalamus, pituitary, gonads and adrenal glands [3]. Pathogenic variants in 
this gene can lead to females with premature ovarian failure. They can also pres-
ent in 46,XY DSD ranging from ambiguous genitalia to female external genitalia 
with complete to incomplete regression of the Müllerian duct derivatives [23–25]. 
Various mutations including p.G35D, p.G35E, p.R92Q and p.R255L have been seen to 
cause adrenal insufficiency combined with gonadal dysfunction. DAX1 is another 
important orphan nuclear receptor with roles in the hypothalamus, pituitary, 
gonads and adrenal glands [26].
The Wilms tumor factor 1 (WT1) pathogenic gene mutations are commonly 
associated with Denys–Drash and Frasier syndrome along with an increased risk for 
nephroblastoma. Denys–Drash classically presents with a triad of symptoms includ-
ing genitourinary abnormalities, renal impairment and Wilms tumor [27]. Frasier 
syndrome classically presents with focal segmental glomerulonephritis (typically 
presenting as later onset renal impairment) and an increased risk for Wilms tumor. 
This risk is not as high compared to other WT1 related conditions. Other genes 
of interest include CBX2 and DHH. CBX2 is involved in both the regulation of 
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homeotic genes and of the bipotential gonad [3]. Pathogenic variants in the CBX2 
gene have presented as a normal female (internal and external genitalia). These 
studies suggest that CBX2 could be responsible for repression of ovarian develop-
ment [28]. In XY individuals with MAP3K1 pathogenic variants are associated with 
suppressing SOX9 and shifting the signaling pathway to promote ovarian differ-
entiation [29]. At approximately 9 weeks of embryonic development Leydig cell 
differentiation occurs involving DHH [3]. Pathogenic variants in DHH can cause 
complete or partial gonadal dysgenesis. They can also be found in minifascicular 
neuropathy (OMIM 605423) [30]. Pathogenic variants in DAX1 can cause congeni-
tal adrenal hypoplasia and hypogonadotropic hypogonadism (OMIM 300473) and 
complete or partial gonadal development with ambiguous external genitalia [4]. 
Other genes associated with XY gonadal dysgenesis include DMRT1, DMRT2, SOX3 
and SOX8 among others [31].
3.2 Disorders of androgen synthesis
Disorders of androgen synthesis are characterized by a lack of Müllerian 
 structures. The testes in 46, XY individuals produce Anti-Müllerian hormone and 
have genital abnormalities including normal female external genitalia.
Two categories can be used to describe Disorders of Androgen Synthesis:
1. Congenital adrenal hyperplasia (CAH) in patients with female  
chromosome sex
2. Associated with normal adrenal function.
Seven enzymes involved in the production of testosterone and dihydrotestos-
terone, responsible for 46, XY disorders of sex differentiation have been identified 
(Figure 5).
Figure 5. 
Steroid hormone synthesis pathway and associated biochemical abnormalities in 46, XY DSD. POR: P450 
oxidoreductase; StAR: steroid acute regulatory protein; 17α-OH: 17α-hydroxylase; 3β-HSD: 3β-hydroxysteroid 
dehydrogenase; 21-OH: 21-hydroxylase; 18-OH: 18-hydroxylase; 11β-OH: 11β-hydroxylase; 17β-HSD: 
17β-hydroxysteroid dehydrogenase; 5α-R: 5α-reductase; CAH: congenital adrenal hyperplasia (adapted from [17]).
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3.2.1 Disorders of androgen synthesis associated with adrenal dysfunction
Defects early in the pathway result in congenital adrenal hyperplasia and adrenal 
insufficiency. These enzymes are present in both the adrenal cortex and the gonads.
The first enzymatic step involves the steroidogenic acute regulatory (StAR) 
protein and p450 oxidoreductase (POR) (Figure 5), these enzymes cause the cleav-
age of cholesterol to pregnenolone. Pathogenic mutaions in the StAR gene lead to 
an autosomal recessive lipoid congenital adrenal hyperplasia (OMIM 201710). The 
condition is characterized by lipid accumulation, severe salt wasting and genital 
ambiguity. This genital involvement ranges from hypospadias to complete female 
external genitalia. P450 oxidoreductase defects are commonly associated with 
Antley-Bixler syndrome with genital anomalies and disorders in steroidogenesis 
(OMIM 201750). P450 oxidoreductase defects have been found with a non– 
syndromic presentation (OMIM 613571) with a similar picture to StAR mutations 
but lacking CAH [32].
3β-hydroxysteroid dehydrogenase (3β-HSD) is the next major enzyme involved 
in multiple steps including converting pregnelone to progesterone, 17α-OH prege-
nelone to 17α-OH progesterone and DHEA to androstenedione. Defects in 3β-HSD 
enzyme activity result in salt wasting and decreased testosterone production result-
ing in genital abnormalities in males. The findings include hypospadias, micropenis 
and bifid scrotum (OMIM 201810).
17α-hydroxylase is involved in the conversion pregnelone and progesterone to 
their 17α hydroxylated forms. Defects to this enzyme pathway also present with 
increased risk for adrenal insufficiency and ambiguous genitalia. Patients present-
ing with a combined deficiency in 17α-hydroxylase and 17,20-lyase present similarly 
to isolated 17α-hydroxylase deficiency. Patients with isolated 17,20-lyase deficiency 
have normal adrenal function and variable abnormalities of male phenotype. This is 
because 17,20-lyase is present in the gonads only.
3.2.2 Disorders of androgen synthesis not associated with adrenal dysfunction
17β-hydroxysteroid dehydrogenase type III (Figure 5) leads to the conversion 
of androstenedione into testosterone, this occurs within the gonads. Pathogenic 
variants cause an autosomal recessive disorder (OMIM 264300) with female external 
genitalia in 46, XY individuals, male gonadal derivatives, absent Müllerian struc-
tures, infertility and decreased testosterone [33]. These patients are sometimes dif-
ficult to distinguish from 5α-reductase deficiency and partial androgen insensitivity 
syndrome [34]. Further biochemical testing with ACTH stimulation or hCG stimula-
tion may be needed [17] although DNA analysis is probably the easiest to perform.
Testosterone and dihydrotestosterone (DHT) are the end products for testis 
steroid hormone synthesis. Pathogenic variants occurring in the 5α-reductase 
gene (SRD5A2) lead to various biochemical changes including low levels of DHT, 
normal/increased levels of testosterone and high testosterone/DHT levels. Patients 
present with undermasculinization of the external genitalia due to low levels of 
DHT [34]. The presentation ranges from a female phenotype to a small phallus with 
severe hypospadias. These patients have normal male internal genitalia and some 
patients may have normal sperm production.
3.3 Disorders of androgen response
The most common cause of 46, XY DSD are the androgen insensitivity 
syndromes (AIS) [OMIM # 300068]. The androgen receptor (AR) is unable to 
activate due to the inability of testosterone or DHT to bind to the receptor [35] 
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(Figure 5). Androgens have a lack of effect on genital development. These condi-
tions are X-linked inherited and present with a wide range in phenotypes. Complete 
Androgen Insensitivity Syndrome (CAIS) has an estimated prevalence of at least 
1:99,000 [36] presenting with normal female genitalia and blind ending vaginal 
pouch. Partial Androgen Insensitivity Syndrome (PAIS) has an estimated preva-
lence of 1:8000. This conditions occurs when there is residual AR receptor function 
and hypospadias are the common finding. Mild Androgen Insensitivity Syndrome 
(MAIS) is the least severe. MAIS usually presents with no genital abnormalities. This 
condition can be suspected in the context of pubertal gynecomastia or unexplained 
infertility [33]. Pathogenic variants in AR have been associated with AIS. These 
pathogenic variants can be located outside of the coding region [37, 38]. There have 
been some cases where no pathogenic variants in AR have been detected. This sug-
gests other proteins located beyond AR that influence testosterone signaling [39].
4. 46, XX disorders of sex development
46, XX DSD can occur due to:
1. Abnormal ovarian development.
2. Excess androgen levels due to abnormal synthesis or androgen exposure.
4.1 Ovarian development
There are two types of abnormal development that can cause XX sex reversal:
1. Patients who have the presence of the SRY gene. This can be caused by a trans-
location of the SRY gene to another chromosome, usually the X chromosome. 
In some rare cases a translocation to an autosome occurs.
2. Patients who are XX males and SRY – negative
Loss of function mutations in genes coding for ovarian formation and function 
are associated with ovarian dysgenesis and/or accelerated loss of primordial folli-
cles. This can cause premature ovarian failure (POF) and/or premature menopause.
The gene responsible for the differentiation of the bipotential gonad into ovaries 
is the WNT4 gene (Figure 4). The WNT4 gene is a member of the WNT family 
of secreted molecules. This family of genes function in a paracrine manner. The 
WNT proteins are ligands to members of the Frizzled (FZ) family of cell surface 
receptors. They are also possibly ligands to the single-pass transmembrane protein 
LDL-receptor-related proteins 5 and 6 (LRP5 and LRP6) [40]. The binding of WNT 
to FZ leads to reduced degradation of β-catenin. This causes β-catenin-dependent 
activation of T-cell factor/lymphocyte enhancer factor transcription factors that 
lead to the induction of WNT – responsive genes [41]. WNT4 is produced in ovarian 
pre-granulosa cells. WNT4 up-regulates the gene DAX1 [42], which antagonizes 
NR5A1, and inhibits steroidogenic enzymes. WNT4 – knockout XX mice have 
been shown to have no Müllerian ducts derivatives, have present Wolffian ducts 
and masculinized with the expression of the steroidogenic enzymes, namely 3β 
hydroxy steroid dehydrogenase and 17α hydroxylase. They are critically important 
in the production of testosterone. Conversely, they are normally suppressed in the 
developing female ovary. Mice models showed ovaries with a decreased number of 
oocytes. This demonstrates the important role of WNT4 in maintaining the female 
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germ cells and thus normal ovarian function [43]. This is contrasted by testicular 
function which continues in the absence of sperm.
In humans, duplication of chromosome 1p31-p35 causes a duplication of the 
WNT4 gene. This duplication has been associated with male to female sex reversal 
exhibiting ambiguous genitalia, severe hypospadias, streak gonads and remnants of 
both Müllerian and Wolffian ducts [42] . Homozygotes with pathogenic variants in 
WNT4 results in SERKAL (SEx Reversion, Kidneys, Adrenal and Lung dysgenesis) 
syndrome [44]. Pathogenic variants in this gene have also been found in women 
with absent Müllerian structures with clinical signs of androgen excess. Pathogenic 
variants have also presented with findings resembling Mayer-Rokitansky-Küster-
Hauser syndrome [45].
Another important gene is the FOXL2 gene which is responsible in the formation 
and function of the ovaries. Pathogenic variants in this gene result in BPES (blepha-
rophimosis, ptosis, and epicanthus inversus) syndrome (OMIM # 110100). There 
are two types of the condition; in BPES I it is associated with premature ovarian 
failure (POF) and in BPES type II it is not associated with POF.
In mice models the continued expression of FOXL2 is essential in maintaining 
ovarian function. Loss of gene expression leads to reprogramming of granulosa and 
theca cells into cells that are similar to Sertoli and Leydig cells, respectively  
[4, 46–49]. FOXL2 also stimulates the expression of the gonadotropin releasing hor-
mone (GnRH) receptor. This expression precedes glycoprotein hormone α-subunit, 
this is a common subunit to FSH, LH, and TSH in the pituitary gland [50].
RSPO1 [roof plate-specific spondin-1] is an important gene in ovarian develop-
ment. It’s role is to act as a regulator of female sex differentiation by activating the 
canonical WNT/β-catenin pathway. This pathway opposes testis formation, with 
WNT4 playing a prominent role as a key ligand [51, 52]. During sex differentiation 
significantly higher expression of RSPO1 was detected in the ovaries compared to 
testis [52], supporting the genes importance in female sex differentiation.
Other genes associated with ovarian dysgenesis and premature ovarian failure 
include: LHX8, MCM8, MCM9, NOBOX, and FSHR [46–48].
4.2 Exposure or overproduction of androgens
In 46,XX female, increased fetal androgen synthesis or prenatal exposure to 
androgen leads to musculinization of the female external genitalia (Figure 6) [26].
4.2.1 Exposure to androgens of non-fetal origin
Maternal androgen producing tumors can cause virilization of a female infant. 
These include adrenal tumors and ovarian tumors. There have been reports includ-
ing a maternal luteoma of pregnancy which caused virilization of both mother and 
child [53]. There are also various drugs with androgenic activity. These include 
androgens, danazol, progestins and potassium sparing diuretics that are known to 
cause virilization [17, 53].
Placental Aromatase Deficiency is another cause of virilization in a female. This 
is a rare autosomal recessive condition caused by mutations in CYP19A1 on chromo-
some 15q21.2 and less than 20 cases have been described in literature. Aromatase 
converts androstenedione to estrone in the female ovaries (Figure 6) providing 
protection for the fetus from high circulating levels of androgens. Sources of andro-
gens include the fetal adrenal glands and androgens of maternal origin [54]. Cases 
present with maternal virilization in the 3rd trimester and abnormal genitalia in the 
affected females [54, 55]. Biochemically cases have intact cortisol and aldosterone 
production and are not at risk for salt wasting.
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4.2.2 Steroid synthesis defects – overproduction of androgens
Steroid synthesis defects leading to congenital adrenal hyperplasia with 
 androgen excess cause clitoral enlargement, partial or complete fusion of the labia 
majora and a short vagina [26] with virilization Prader stage above III [55].
The most common cause of 46, XX disorders of sexual differentiation 
(Figure 6) is 21-hydroxylase (21-OH) deficiency. This occurs in 90% of cases [55] 
and has a prevalence of 1:14,000–1:15,000 worldwide [54, 55]. This autosomal 
recessive condition is caused by mutations in the 21-OH gene (CYP21A2) on 
chromosome 6p21.1. The severity of the disease correlates generally to the degree of 
enzyme activity with classic 21(OH) deficiency having less than 5% activity. These 
patients present with congenital adrenal hyperplasia and in utero virilization of the 
external genitalia in females. Non-classic 21(OH) deficiency have >15% residual 
activity. These patients present with androgen excess in adolescence and early 
adulthood [54].
Patients with classic 21(OH) deficiency are at high risk (approximately 
70%) for neonatal salt wasting [17]. These patients present with high 
17α-hydroxyprogesterone, androstenedione and testosterone levels (Figure 6) 
and decreased sodium, elevated potassium and elevated renin at the end of the 
first week of life [17]. The high androgens levels result in virilization of the female 
external genitalia in female fetuses. This can be seen as early as 12 weeks gestation 
[54] and varies from mild clitoromegaly to complete male external genitalia with 
rugated and pigmented labioscrotal folds and a phallic structure [17].
Non-classic 21(OH) deficiency is more common than the classic form. The world 
wide incidence is 1:300, the Ashkenazi Jewish population has a higher incidence 
described as 1:27 [54]. They generally present in adolescence with a presentation 
is similar to Polycystic Ovarian Syndrome, namely premature pubarche, acne, 
 hirsutism and irregular menses.
11β-OH is present in the adrenals and coded by the CYP11B1 gene. Defects lead 
to congenital adrenal hyperplasia which present with a similar picture to classical 
CAH. This is the second most common cause of congenital adrenal hyperplasia 
Figure 6. 
Steroid hormone synthesis pathway in 46, XX DSD. 3β-HSD: 3β-hydroxysteroid dehydrogenase; 21-OH: 
21-hydroxylase; 11β-OH: 11β-hydroxylase (adapted from [17]).
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with an incidence of less than 1:100,000 births. The condition is inherited in an 
autosomal recessive manner and homozygote or compound heterozygote mutations 
in the CYP11B1 gene (mapped to chromosome 8q21-q22) results in a loss of enzyme 
function [54]. The most common mutation in the CYP11B1 gene is the R448H 
mutation, which is also the founder mutation identified in Moroccan Jews who has a 
high prevalence of the condition [54]. Patients with 11β-OH deficiency present with 
virilization of the external genitalia due androgen excess; biochemically this is seen 
as elevated 11-deoxycortisol and 17α-hydroxypregnelone (Figure 6) [17]. These 
patients have normal aldosterone production and thus a decreased risk of salt wast-
ing. Aldosterone synthesis is mediated by the CYP11B2 gene, which is homologous 
to CYP11B1 and located within 40 kb [54]. This results in normal levels of deoxy-
corticosterone and aldosterone and a wide range of blood pressure phenotypes have 
been reported [26, 54].
There are rare forms of defects in steroid synthesis causing CAH. These include 
3β-hydroxysteroid dehydrogenase (3β-HSD) deficiency and 11β-hydroxylase  
(11β-OH) deficiency. There are two enzymes that mediate 3β-HSD. The type 1 
enzyme (HSD3B1) is present in the skin, liver, peripheral tissues and placenta and 
the high levels of dehydroepiandrosterone are converted to androstenedione and 
then to testosterone and DHT [54]. The degree of virilization is moderate compared 
to 21-OH deficiency. Patients present with mild to moderate clitoromegaly and 
rarely fusion of the labioscrotal folds (Figures 5 and 6) [54, 55].
Type 2 (HSD3B2) deficiency is a rare condition occurring in 1:1,000,000 births. 
This condition presents with severe salt wasting similar to 21-OH deficiency and 
less severe virilization [54, 55]. This is an autosomal recessive condition caused by 
mutations in the HSD3B2 gene, located on chromosome 1p13. As with other forms 
of CAH, the severity of the disease correlates with the degree of enzyme activity 
[54, 55]. Type 2 deficiency leads to impaired aldosterone and cortisol production 
presenting biochemically with elevated pregnenolone, 17(OH) pregnenolone and 
elevated dehydroepiandrosterone (Figure 6) [17, 55]. This leads to salt wasting, 
hyperkalemia and volume depletion similar to 21(OH) deficiency. Virilization 
occurs in a similar fashion to 11β (OH) deficiency.
5. Investigations
The initial investigation should include a careful physical examination to deter-
mine if the presentation is isolated or non-isolated (Figure 1). In view of the asso-
ciation between IUGR and undervirilization in chromosomal male fetuses, results 
of maternal serum screening, placental growth factor and detailed fetal ultrasound 
findings and biophysical profile as well as the birth weight should be obtained.
Examination of the external genitalia should include:
a. Assessment of the labioscrotal folds—the labioscrotal folds should be 
assessed for pigmentation, rugation, asymmetry and fusion. High insertion 
of the labioscrotal folds (above the penis) as well as “buried penis” should be 
 differentiated from micropenis.
b. Assessment of the phallic structure, the length, breadth, urogenital open-
ings—the phallic structure should be assessed for length, breadth, chordee 
and relationship with the labioscrotal folds looking for complete or incomplete 
penoscrotal transposition. The normal penile length at term is 3.5 cm with 
2.5 cm being at −2SD. The normal clitoral length at term is 2–8.5 mm and 
breadth 2–6 mm [56].
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c. Location, structure and volume of the gonads—gonads located in the  inguinal 
canal and labioscrotal folds are always testes although ovotestes is also a 
possibility.
The perineum should also be examined for the number and position of the 
openings and then compared to the Prader scale [57].
Investigations should be targeted to identify:
1. The chromosome sex
2. The gonadal sex
3. The internal genitalia [using ultrasound and/or MRI to find if], is there is a 
uterus, is the uterus normal and are there intrabdominal gonads
4. The external genitalia
Since gonads in the inguinal canal and labioscrotal folds are almost always testis 
finding them on palpation usually indicates the existence of the SRY gene. However, 
the chromosome sex should be determined using quantitative fluorescent PCR 
(QF-PCR) or fluorescent in-situ hybridization (FISH) analysis. Microarray analysis 
should be completed, looking for submicroscopic deletion or duplication involving 
the SRY gene as well as other chromosome abnormalities [58].
Unique situations to be aware of include the most severe cases (46,XY with 
complete feminization and 46,XX with complete masculinization) it is difficult 
to diagnose an abnormal phenotype. Other scenarios include isolated grade 1 
(glandular) and 2 (penile shaft) hypospadias, especially when associated with 
intrauterine growth restriction (IUGR) the investigative yield is low. Most cases 
are the result of the IUGR – Placental dysfunction – abnormal genitalia syndrome 
[59]; however, since this is a diagnosis by exclusion and there is no objective way 
of differentiating the condition from PAIS and mild 5α reductase deficiency, 
DNA analysis using 46,XY panel or for these conditions is recommended. Further 
investigations are also indicated with hypospadias associated with bilateral or 
unilateral undescended testes, micropenis, clitoromegaly, posterior fusion of the 
labia majora.
The most common cause of abnormal genitalia in female is CAH. When initial 
investigations show XX karyotype, 17-hydroxyprogesterone (17-OH) and renin at 
48 hours of age (after the surge of adrenal hormones at birth) should be done. The 
abnormal sodium and potassium blood levels will present only in the second week 
of life.
In cases with XY karyotype, the testosterone, LH and FSH levels should be 
measured looking for low testosterone and dihydrotestosterone (DHT) levels. 
Answering the above four questions will guide further investigations which include 
assessment of adrenal function, testicular function and internal genitalia using 
ultrasound, MRI and/or genitogram or laparoscopy [17].
Genetic testing plays an important role in finding the etiology and thus provid-
ing genetic counselling regarding the recurrence risks and the prenatal/preimplan-
tation options in future pregnancies. The use of DSD genetic panels can investigate 
multiple genes simultaneously and accelerate the diagnostic process. Using massive 
parallel sequencing looking at a variety of genes causing DSD in a cohort of 278 
patients with 46, XY DSD and 48 with 46, XX DSD of an unknown etiology, Eggers 
et al., found a likely genetic diagnosis in 43% of patients with 46, XY DSD and 17% 
of patients with 46, XX DSD [60]. If no gene mutation is identified, whole exome/
genome sequencing is recommended.
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6. Gender assignment
When a newborn presents with ambiguous genitalia, a thorough physical exami-
nation, as well as various genetic (e.g. karyotype, microarray) and non-genetic inves-
tigations are ordered. From this, the health care team is able to have discussions with 
parents regarding the gender for sex of rearing. With regards to genital surgery, the 
current suggestion is that if genital surgery is not medically indicated, then to wait 
until the patient him/herself is able to make this decision. In cases with substantial 
ambiguity such as in PAIS, mixed gonadal dysgenesis, ovotesticular DSD and females 
with CAH and severe masculinization, a multidisciplinary DSD team including 
pediatric endocrinologists, geneticists, genetic counsellors, urologists, gynecologists, 
social workers and psychologists/psychiatrists with expertise in this field should 
be part of the care team. The findings, plan for investigations, gender assignment 
and treatment should be discussed among the group members prior to meeting the 
parents. Factors which have to be taken into consideration include type of gonads and 
potential function of these, present or future treatment with hormones, including 
for inducing puberty or for fertility if this can be predicted, as well as any medically 
necessary surgical treatment. When meeting with the parents, the team should pres-
ent this information at a level that the parents can understand, using visual aids to 
facilitate the discussion. At the same time, if information is known from the litera-
ture about certain conditions that parents should be aware of, e.g. female babies with 
CAH and exposure to high and early levels of androgen levels prenatally can show 
more behaviors attributable to the male personality and sexual orientation [61–64], 
and the challenges in repairing severe hypospadias in patients diagnosed with PAIS 
[65], then this should be shared with them. In this way, the parents, together with the 
healthcare team’s input can come to an informed decision about sex of rearing.
7. Gonadal cancer risk
Dysgenetic gonads with a Y chromosome material are associated with an 
increased risk for malignancy, mainly gonadoblastoma, dysgerminoma and germ 
cell tumors, including seminoma, non-seminoma, juvenile granulosa cell and germ 
cell neoplasia in situ [66, 67]. Gonadoblastoma (GB) presents with a mixture of 
germ cells and stromal elements as well as immature Sertoli cells and may contain 
calcifications with pure gonadoblastomas being not metastatic. About 80% of 
patients with GB are phenotypic females and 20% are phenotypic males, many of them 
with hypospadias and bilateral or unilateral cryptorchidism. The incidence of GB in 
dysgenetic gonads varies from 4.7% to as high as 25%. Germ cell neoplasia in-situ 
cells are found lining the seminiferous tubules in dysgenetic testes and resemble 
immature germ cells. Thus, they cannot be diagnosed before puberty when they 
are normally present. However, when found in the testes in late childhood or post 
puberty they are pathological and are capable of transforming into seminomas 
in males and dysgerminoma in females and this tumor can metastasize. Removal 
of the gonad prior to puberty in patients with complete androgen insensitivity 
is controversial in view of the data indicating low risk for malignancy until early 
adult years [68, 69]. In these patients, if the testes are located in the labia majora, 
they are amenable to ultrasound surveillance and biopsies, if needed which makes 
post-pubertal monitoring simpler. When the testes are undescended, laparoscopic 
gonadopexy to bring them near the anterior abdominal wall to allow surveillance 
may be an option for patients who decide to avoid gonadectomy [68, 69]. Delayed 
surgery can help in involving the patient in the decision making [67, 70, 71]. 
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Persistent Mullerian Duct Syndrome is associated with the usual cancer risk associ-
ated with cryptorchidism as well as an unknown incidence of a possible tumor risk 
of the Mullerian duct structures.
8. Genetic counseling and DSD
In 2006, a new definition of genetic counseling was published in the Journal of 
Genetic Counseling, by a task force that was convened by the National Society of 
Genetic Counselors (NSGC). The definition is as follows: “Genetic counseling is the 
process of helping people understand and adapt to the medical, psychological and 
familial implications of genetic contributions to disease. This process integrates the 
following:
a. Interpretation of family and medical histories to assess the chance of disease 
occurrence or recurrence.
b. Education about inheritance, testing, management, prevention, resources and 
research.
c. Counselling to promote informed choices and adaptation to the risk or 
 condition” [72].
Genetic counselling has an important role in the management of DSD patients 
and their families. In most cases, counselling involves the woman/couple, following 
the birth of a child with DSD and/or in discussing the implications of their future 
reproductive plans. Genetic counselling can also be extended to other family mem-
bers and the implications to themselves and their future pregnancies. Discussions 
with other family members require consent from the parents of the index patient or 
the index patient himself/herself if of age of maturity. Other indications for genetic 
counselling include an adolescent or young adult with DSD who wishes to learn 
more about their own diagnosis and the implications for her/his reproductive plans 
as well a woman/couple during their pregnancy when discordance between the 
genotypic and phenotypic sex is identified.
Following the birth of a child with DSD, parents are often overwhelmed and 
confused by their child’s condition. Although gender assignment and naming of the 
child are pressing issues for the parents, these actions should not be unduly rushed. 
Parents should be provided with information so as to help them in making informed 
decisions, together with their healthcare team. Adequate counseling and support 
for parents includes education regarding sexual development in utero (including 
brain imprinting of gender identity), genetic counseling, ethical considerations of 
the child’s rights to make decisions regarding gender, and information regarding 
current guidelines and recommendations.
A three generation family history should be obtained with careful inquiry. 
Information about family history of infertility, women with no menstrual peri-
ods, stillbirth, recurrent miscarriages, neonatal death, congenital abnormalities, 
intellectual disabilities and consanguinity should be obtained. When drawing the 
family history, it should be kept in mind that chromosome sex and phenotypic sex 
may be interpreted differently by the family; for the family, it is the phenotypic 
sex that identifies the family members as male or female (versus chromosome 
sex). Furthermore, in X-linked conditions the phenotypic infertile female may be 
chromosomally male (such as in androgen insensitivity or ATRX).
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When a diagnosis is established from genetic investigations, then the family can 
be provided with information regarding the clinical manifestations and natural his-
tory, mode of inheritance, medical management recommendations, if any, recur-
rence risk for future pregnancies, implications to their other children/other family 
members, as well as information regarding appropriate patient support groups. 
Cultural differences need to be respected and taken into consideration during the 
counselling process [73].
In some cases, a DSD is diagnosed incidentally during pregnancy, with no 
 previous family history. This could be following the finding of fetal abnormal 
external genitalia or finding of discrepancy between the phenotypic sex as deter-
mined by fetal ultrasound and the genotypic sex as determined by chorionic villus 
sampling, amniocentesis or non-invasive prenatal testing (NIPT) done for other 
reasons. The differential diagnosis for the cases detected incidentally is broad but 
it should be kept in mind that in a 46,XX fetus, the most likely diagnosis is con-
genital adrenal hyperplasia. In a 46,XY fetus, the differential diagnosis includes a 
variety of conditions including androgen insensitivity syndrome, 46,XY gonadal 
dysgenesis and testosterone biosynthesis defects, when no other abnormalities are 
identified. When other abnormalities are detected, such as on ultrasound, more 
rare conditions such as campomelic dysplasia and Smith-Lemli-Opitz syndrome 
should be considered [74]. Following prenatal diagnosis of a DSD the family may 
choose to continue with the pregnancy with no further investigations, they may 
decide to terminate the pregnancy based on the information provided or they 
may decide to further investigate the etiology of the abnormalities identified. Prior 
to this however, the genetics health care team should facilitates a discussion with 
the family outlining each option with the pros/cons of each, including what to 
expect from a procedure, if applicable, as well as the impact on puberty and fertility 
and the potential psychosocial perspective. This information is important to allow 
an informed decision to be made in keeping with their value and belief system. 
The family should be made aware that the genetics health care team will support 
whatever decision they make. In situations where the family decides to terminate 
the pregnancy and the etiology of the condition is not known, the benefits of a fetal 
autopsy and molecular analysis should be reviewed with the family.
Genetic counselling should be made available to couples who are planning to 
have more children, following the birth of a child with DSD. The provision of 
genetic counselling in these cases, in addition to providing psychosocial support, 
includes information regarding their recurrence risk and their available reproductive 
options:
1. Accepting the risk of having another affected child and have no prenatal/ 
preimplantation genetic diagnosis.
2. Deciding not to have any more biological children and choosing instead to use 
donor gametes, donor embryos or adoption.
3. Conceive naturally and have pre-natal diagnosis with the option of either 
 continuing or terminating an affected pregnancy.
4. Pre-implantation genetic diagnosis (PGD).
Patients with DSD may be infertile. For these patients, conception using 
donor gametes and/or surrogate mother may be possible and should be discussed. 
However, to lower the recurrence risk, when applicable, the donor should not be a 
genetic relative/carrier of the condition.
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9. Conclusion
Normal sex development includes determination of chromosome sex, gonadal 
sex, development of internal and external genitalia as well as the psychosocial sex. 
This is a complex process involving genetic and non-genetics components, many 
of them are yet unknown. Disorder of sex development is an etiologically a heter-
ogenous group of disorders with a major lifelong impact on the patients and their 
families.
In view of the complexity of these group of patients they should be seen by a 
DSD team including but not limited to pediatric endocrinologist, pediatric urolo-
gist, medical geneticist, genetic counsellor, psychologist/psychiatrist and social 
worker and the findings and current knowledge should be presented to the parents 
so that they can make an informed decision regarding the gender, when appropri-
ate. The child with DSD should continue be followed into puberty and adulthood 
to achieve optimal treatment, psychosocial well-being, sexual satisfaction, and 
fertility in view of the patients gender role and identity [75].
10. Resources
10.1 Web based resources
Web-based educational resources for families include:
www.aboutkidshealth.ca/En/HowTheBodyWorks/
SexDevelopmentAnOverview
This website provides detailed graphically illustrated explanations of sex devel-
opment and DSDs that health professionals can use when working with families.
10.2 Support groups
Androgen Insensitivity Syndrome: Differences of Sex Development Support 
Group.
http://aisdsd.org/
CARES foundation: Congenital Adrenal Hyperplasia Research, Education and 
Support.
http://www.caresfoundation.org
Hypospadias and Epispadias Association.
http://heainfo.org
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